key: cord-1022933-ezkuosv8
authors: Li, Matthew; Razaki, Hamid; Mui, Victoria; Rao, Premprakash; Brocavich, Sheila
title: The Pivotal Role of Pharmacists During the 2019 Coronavirus Pandemic
date: 2020-06-01
journal: J Am Pharm Assoc (2003)
DOI: 10.1016/j.japh.2020.05.017
sha: 3de665f063f3bf0b1bd67a259187ab667d37475f
doc_id: 1022933
cord_uid: ezkuosv8

Summary The Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected over three million patients worldwide with an estimated mortality rate of 5%. Owing to the diversity of training and variety of positions within the pharmacy department, pharmacists are uniquely positioned in the hospital setting to play a pivotal role during the pandemic. The purpose of this article is to highlight the experiences and impactful interventions made by pharmacists practicing in a community teaching hospital at the center of the COVID-19 surge in New York City. Although often underrecognized, pharmacists are well-equipped to develop treatment plans based on the evolving literature, positively impact patient outcomes by responding to inpatient emergencies, and optimize medication orders to conserve and maintain a healthy supply of medications for the hospital.

The Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected over three million patients worldwide with an estimated mortality rate of 5%. Owing to the diversity of training and variety of positions within the pharmacy department, pharmacists are uniquely positioned in the hospital setting to play a pivotal role during the pandemic. The purpose of this article is to highlight the experiences and impactful interventions made by pharmacists practicing in a community teaching hospital at the center of the COVID-19 surge in New York City. Although often underrecognized, pharmacists are well-equipped to develop treatment plans based on the evolving literature, positively impact patient outcomes by responding to inpatient emergencies, and optimize medication orders to conserve and maintain a healthy supply of medications for the hospital.

The Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly on a global scale. As of May 8th, 2020, COVID-19 has affected over three million patients and resulted in more than 270,000 deaths worldwide. 1, 2 Curtailing the spread and providing treatment for COVID-19 has required the dedicated and joined efforts of a multidisciplinary healthcare team. Each member of the patient care team brings their expertise to the table, such as the intensivist who recommends the safest way to intubate a patient, the clinical nurse manager who ensures all staff on the unit are equipped with the appropriate personal protective equipment (PPE), or the respiratory therapist that coordinates the availability of viral filters and ventilators.

Owing to the diversity of training and variety of positions within the pharmacy department, pharmacists are uniquely positioned in the hospital setting to play a pivotal role in emergency management. The purpose of this article is to highlight the experiences and interventions of pharmacists at New York City Health & Hospitals/Queens, a 253-bed community teaching hospital staffed by medical residents, school of medicine faculty, and pharmacy specialists in infectious diseases and critical care, to serve as a model for other institutions in the future.

The data supporting specific pharmacologic treatment modalities is continuously evolving as more is known about the disease. The pharmacists' knowledge of research design and their ability to critically analyze the literature places them in an essential position to recommend and modify therapy based on the best supporting evidence. During the first days of the COVID-19 surge, critically-ill patients presented to our institution before any formal treatment recommendations were established. Therefore, our first critically-ill COVID-19 positive patients were initiated on a regimen consisting of chloroquine and lopinavir/ritonavir based on in-vitro and anecdotal data. 3, 4 That same week, Gautret and colleagues published their experiences utilizing a combination of hydroxychloroquine and azithromycin, demonstrating a significant reduction of viral carriage compared to untreated patients. 5 The very next day, Cao and colleagues published a study highlighting the lack of benefit observed with lopinavir/ritonavir beyond standard of care. 6 By the end of the week, after our pharmacists presented this data during patient care rounds, all of our COVID-19 positive patients were transitioned to regimens consisting of hydroxychloroquine and azithromycin. We then continued to routinely utilize the combination of hydroxychloroquine and azithromycin for all COVID-19 patients up until more robust evidence was published demonstrating a lack of clinical benefit and potential risk for harm with the two medications. 7, 8 Our current treatment for COVID-19 now consists mainly of supportive care and the occasional use of investigational therapy such as the anti-viral remdesivir or the interleukin-6 inhibitor tocilizumab. 9,10 Future treatment regimens are still liable to change given the dynamic nature of the pandemic, low-quality of existing literature and large number of ongoing studies. One of the most important things to take into consideration when deciding to implement additional treatment modalities in the era of social media is the underlying quality of evidence.

One example was the request to utilize ivermectin for the treatment of COVID-19 after seeing an internet blog post quoting a 5000-fold reduction in viral concentrations at 48 hours. 11 However, upon a closer analysis of the quoted study, it was clear that it may not be in the patient's and hospital's best interest to initiative therapy based on the findings of one in-vitro study, with no correlation to safe and efficacious dosing in humans. As members of various hospital committees such as Pharmacy and Therapeutics, critical care, and antimicrobial stewardship, pharmacists are able to utilize their knowledge of the literature to play a direct role in the decision-making process for institutional treatment algorithms and therapy restrictions. As the pandemic continues to evolve, pharmacists should stay wellversed in the emerging literature in order to ensure patients are receiving optimal pharmacotherapy.

There is much debate regarding the provision of de-centralized pharmacy services during the COVID-19 pandemic out of concern for the safety of the pharmacists. Despite the increased health risk, we continued to provide our critical care pharmacy services consisting of direct patient care rounds and response to inpatient emergencies. According to the Society of Critical Care Medicine, efforts must be taken to minimize exposure to healthcare workers and maximize the chances of success during endotracheal intubation by having the most experienced healthcare professional with airway management perform the procedure. 12 We believe this same principal should be extrapolated to inpatient cardiac arrests, with experienced pharmacists utilizing their knowledge of advanced cardiovascular life support (ACLS) and pharmacology to manage the medications during inpatient cardiac arrests. This principle is supported by previous data demonstrating decreased patient mortality when a pharmacist is integrated in the cardiopulmonary resuscitation team. 13 During the early weeks of the COVID-19 surge in New York City, our critical care pharmacist responded to approximately four cardiac arrests a day, fully gowning up and entering the room with the other members of the resuscitation team in an effort to reduce contamination to the rest of the unit and to play an active role in therapy management. By serving as the responder in charge of the medications, our pharmacy services were able to alleviate the strain of high nurse to patient ratios during these emergencies. In addition to cardiac arrests, pharmacists play a crucial role in rapid sequence intubation through facilitating the most appropriate selection and dosing of sedatives and paralytics. 14 During the COVID-19 surge, our department prepared custom rapid sequence intubation kits consisting of etomidate, propofol, and rocuronium to be stored in our automatic dispensing cabinets at an adequate quantity to ensure the medication would always be available in the event of simultaneous intubations.

Minimizing the number of entries into COVID-19 positive patient rooms is an essential strategy to decrease the risk of transmission and decrease the use of PPE. Pharmacists are well positioned to assist our nursing colleagues in this effort by having medication orders synchronized as much as possible without compromising on the efficacy of the therapy or safety of the patient. In our experience, certain critically-ill patients with COVID-19 pneumonia would require high dose sedative and paralytic continuous infusions to maintain appropriate oxygen saturations. In order to meet this demand, pharmacists utilized their knowledge of drug compatibility and stability to create custom orders in the electronic medical record for providers that can hold larger volumes, effectively decreasing the number of bag changes performed by the nurse. A variety of investigational drug therapy has been initiated for the management of COVID-19 at our institution. Our infectious diseases clinical specialist was able to coordinate with our informatics team to facilitate the safe use of these agents through the development of order sets and custom orders in the electronic medical record.

A major concern during the pandemic is not having enough medication to treat our critically ill patients. Our pharmacists in charge of procurement have worked diligently through coordinated efforts with our critical care and infectious diseases pharmacy specialists and pharmacy leadership to maintain an adequate supply of medications anticipated to be used frequently in the management of COVID-19 patients. These medications include but are not limited to anti-infective agents, neuromuscular blocking agents, non-benzodiazepine sedatives, analgesics, and vasopressors. Strategies to mitigate the risk of local drug shortages include frequently monitoring the institution's distribution center supply, reaching out to other institutions regarding their current purchase patterns, and dealing directly with generic manufacturers and their representatives. In addition to acquisition, pharmacists should also serve as key members in multi-disciplinary meetings with hospital leadership to develop a protocolized approach to treatment in an effort to conserve drug supply. For instance, our institution experienced a shortage of cisatracurium, a neuromuscular blocking agent commonly utilized to promote ventilator synchrony in patients with acute respiratory distress syndrome. 15 In accordance with the Surviving Sepsis Campaign guidelines for managing critically ill patients with COVID-19, we encouraged providers to utilize bolus dosing of paralytics when able before committing to a continuous infusion while preparing guidelines to utilize rocuronium and vecuronium as alternatives. 12 In the event of a fentanyl shortage, our institution prepared a guideline outlining alternative treatment regimens, utilizing intermittent intravenous push-doses of longer-acting opioids such as hydromorphone.

Pharmacists are well-equipped to develop treatment plans based on the evolving literature, positively impact patient outcomes by responding to inpatient emergencies, and optimize medication orders to conserve and maintain a healthy supply of medications for the hospital. As the COVID-19 pandemic continues to progress, it is critical to recognize and utilize the multi-faceted services provided by pharmacists to facilitate optimal patient care and support for our healthcare colleagues.

An interactive web-based dashboard to track COVID-19 in real time

COVID-19 Dashboard by the Center for Systems Science and Engineering

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv

Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an openlabel, randomized, controlled trial. medRxiv

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet

The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro

Surving Sepsis Campaign: Guidelines on the Managment of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)

Clinical Pharmacy Services, Pharmacy Staffing, and Hospital Mortality Rates

Rapid-sequence intubation and the role of the emergency department pharmacist

Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome